The moral of this story for Cydy is that when you are no longer and insider “you are no longer an insider” and are not privy to the goings on of the company. That’s a good thing , contrary to the Nader regimen with insider trading and self enrichment. Nader left a dumpster fire of multiple major obstacles:
major debt with toxic lenders Tens of millions of unpaid past due invoices to vendors SEC and DOJ investigations plummeting stock price lost credibility with FDA and the public ( clinical holds and such) No money in the til.
The financials are dire with severe difficulty in raising new capital. BK is a real threat, though difficult to predict timing. Credit to the current team for giving their best shot. Doubtful they will be able to turn this around with no capital and trials unavailable. Dubious future for Cydy.
Market Data 
Markets 
AI
